Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
The risk of negative renal outcomes, including CKD upgrading, increases along with duration of acute kidney injury following partial nephrectomy
Platelet levels above 250,000/μL prior to surgery for high-risk renal cell carcinoma are independently associated with a 1.5-fold increase risk for recurrence.
Positive surgical margins in patients undergoing partial nephrectomy for cT1b renal cell carcinoma are associated with worse 5-year recurrence-free and overall survival.
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
In a study, left-sided renal cell carcinoma (RCC) was associated with a 16% to 19% increased risk of dying from the malignancy compared with right-sided RCC.
In the contemporary era of more effective systemic therapies, complete surgical resection of RCC metastases is associated with improved survival, new findings suggest.
Delaying surgery more than 10 weeks after diagnosis of pT3 renal cell carcinoma is associated with increased 5-year mortality risk.
Study of patients on active surveillance for renal cell carcinoma showed spontaneous tumor regression occurred more often among those with papillary or chromophobe than clear-cell histology.
